Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now later-stage tilt small index

Cardiac Toxicity: later-stage trial registry

2 of 7 indexed Cardiac Toxicity trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 2 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Cardiac Toxicity: 7 US clinical trials tracked, 2 recruiting.

Cardiac Toxicity is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Oncology Group, running 2 of these trials.

Enrollment posture brief

Registry condition cardiac-toxicity

OPEN 2 | RECR 29% | LATE 3 | EARLY 1 | RANK #2497 | SPON 2

Nearest open-share peer: Acromegaly (29% recruiting · 14 trials)

ACL Tear71.4%ACL57.1%Acute Myelogenous Leukemia42.9%Cardiac Toxicity (this)29%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Cardiac Toxicity

Cardiac Toxicity lists 2 open slots (29% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cardiac Toxicity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cardiac Toxicity is recruiting below its size-band peers.

    2 of 7 indexed trials (28.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Cardiac Toxicity research.

    Children's Oncology Group accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cardiac Toxicity enrolment sits around 133 participants.

    Median target enrolment is 133 among the 7 trials that report a genuine target (sentinel values excluded). 3 of those (42.9%) plan for fewer than 100 participants.

  4. Cardiac Toxicity research is mostly interventional.

    5 interventional and 2 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21Phase 32Phase 41

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Cardiac Toxicity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

doxorubicin hydrochloride Drug
2 trials
enalapril maleate Drug
1 trials
bleomycin sulfate Biological
1 trials
Computerized Intervention Authoring Software (CIAS) Behavioral
1 trials
management of therapy complications Procedure
1 trials
dexrazoxane hydrochloride Drug
1 trials
filgrastim Biological
1 trials
polymorphism analysis Genetic
1 trials

US sites by state

Facility locations filed on Cardiac Toxicity trials. A trial with sites in several states counts in each.

California 3 trials
New Jersey 2 trials
Missouri 2 trials
Illinois 2 trials
Colorado 2 trials
Arkansas 2 trials
Alabama 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cardiac Toxicity page

7 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cardiac Toxicity condition card totals 7 registered trials; most-linked intervention doxorubicin hydrochloride; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.